ClinicalTrials.gg
CompletedNCT00185237Updated Dec 23, 2014

Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch

A Phase 3 interventional study of Menostar (estradiol transdermal delivery system) and Placebo in Hot Flashes, sponsored by Bayer. Completed. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-23.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
10th of 13
165 · median 431
Started
2005
with 1 other
Phase 3
8 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
4 of 13
Bayer

Among the 13 studies testing estradiol in Hot Flashes, this one is the 10th largest by enrollment, is one of 2 that started in 2005, is one of 8 in phase 3, and was the 1st registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

150 postmenopausal Asian women with vasomotor symptoms, after fulfilling the inclusion and exclusion criteria will be enrolled in the study. The women will be randomly assigned to one of two treatment groups (Menostar® or placebo), after which they will be asked to use a patch once a week for 12 weeks.

Read the detailed description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Menopause
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of status

Exclusion criteria

Exclusion Criteria:

  • to estrogen therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Menostar (estradiol transdermal delivery system)

  • Placebo comparator
    Arm 2

    Drug: Placebo

Interventions

  • DrugMenostar (estradiol transdermal delivery system)

    Drug pages: Estradiol · Ethinyl Estradiol

    Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)

  • DrugPlacebo

    Placebo patch

06

What researchers measure

Primary outcomes

  1. Relative change in frequency of hot flushes

    Time frame: 12 weeks

Secondary outcomes

  1. Change in intensity of hot flushes

    Time frame: 12 weeks

  2. Changes in vaginal pH

    Time frame: 12 weeks

  3. Changes in vaginal maturation index

    Time frame: 12 weeks

  4. Occurrence of urogenital symptoms

    Time frame: 12 weeks

  5. Change in MENQOL (menopausal quality of life questionaire)

    Time frame: 12 weeks

  6. Bleeding profile

    Time frame: 12 weeks

  7. Safety

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 16, 2005
Start
Jul 2005
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Dec 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00185237
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
Jul 2005
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Dec 23, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Ethinyl Estradiol

Start the discussion